PDCD1 and non-small cell lung carcinoma: By comparison, NSCLC-expanded PD-1+CD8+ T cells activated by anti-CD3 were highly sensitive to PD-L1 inhibition with only minimal rescue of function in the presence of atezolizumab (Extended Data Fig. 7b,c).